On a Tuesday at the end of last semester, I asked my first-year writing class how they were using AI in their courses. One of ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

The reported valuation aligns with where Manus had been headed before Meta intervened. The company had been raising new funds ...

There’s something magical about watching movies under the stars, and the Admiral Twin Drive-In in Tulsa delivers that enchantment with a double dose of nostalgia that’ll make you feel like you’ve time ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Cathie Wood’s ARK Investment Management sharply increased its exposure to AI-driven biotechnology and cryptocurrency during ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Khadija Khartit is a strategy, investment, and funding expert, and an educator of fintech and strategic finance ...